For immune globulins, please see section 14.2 Immunoglobulins

Interferons

Interferon alfa – 2a

• Roferon-A pre-filled syringe

Interferon alfa – 2b

• IntronA injection pen
• IntronA injection

Interferon beta – 1a

• Avonex injection
• Rebif injection

Notes

1. NICE TA527: Interferon beta-1a is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing-remitting MS, and the companies provide it according to commercial arrangements (June 2018) (NHS England Commissioned)

Interferon beta – 1b

• Extavia injection

Notes

1. NICE TA527: Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing–remitting MS and has had 2 or more relapses within the last 2 years, or the person has secondary progressive MS with continuing relapses, and the company provides it according to the commercial arrangement (June 2018) (NHS England Commissioned)
2. NICE TA527: Interferon beta‑1b (Betaferon) is not recommended as an option for treating MS (June 2018) (NHS England Commissioned)

Peginterferon alfa - 2a

• Pegasys pre-filled pen

Peginterferon alfa – 2b

• ViraferonPeg pre-filled pen

Notes

1. NICE TA75: Peginterferon alfa, interferon alfa and ribavirin for chronic hepatitis C (January 2004)
2. NICE TA106: Peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin (November 2007)
3. NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part review of TA75 and TA106) (September 2010)
4. NICE TA96: Peginterferon alfa-2a (February 2006)
5. NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (November 2013)

Peginterferon beta - 1a

• Plegridy solution for injection pre-filled pen 63micrograms/0.5ml, 94micrograms/0.5ml, 125micrograms/0.5ml

Notes

1. NICE TA624: Peginterferon beta‑1a (Plegridy) is recommended, within its marketing authorisation, as an option for treating relapsing–remitting multiple sclerosis in adults (February 2020).

Other immunostimulants

Glatiramer acetate

• Copaxone solution for injection pre-filled syringes 20mg/1ml, 40mg/1ml

Notes

1. NICE TA527: Glatiramer acetate is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing-remitting MS, and the company provides it according to the commercial arrangement (June 2018) (NHS England Commissioned)

Mifamurtide

• Powder for suspension for infusion vials 4mg

Notes

1. NICE TA235: Mifamurtide recommended for the treatment of osteosarcoma (October 2011).